Skip to main content
. Author manuscript; available in PMC: 2011 Sep 12.
Published in final edited form as: J Alzheimers Dis. 2011;25(3):445–453. doi: 10.3233/JAD-2011-101980

Table 2.

Demographics, pathological, and clinical information about ‘CERAD[31]-positive’ cases with Braak stages V and VI pathology (evaluated within 3 years of death) in the NACC registry and the Nun Study

Braak V Braak VI p value
NACC cases, n 568 651
Adjusted* Final MMSE score, Mean ± SEM 11.0 ± 0.4 8.0 ± 0.3 <0.0001
Male gender, n (%) 282 (49.7) 335 (51.5) 0.53
Age at death, Mean ± SEM 83.8 ± 0.3 79.5 ± 0.3 <0.0001
Maximum education level in years, Mean ± SEM 14.6 ± 0.1 14.2 ± 0.1 0.046
Neocortical Lewy bodies, n (%) 66 (11.6) 51 (7.8) 0.025
Hippocampal sclerosis, n (%) 58 (10.2) 56 (8.6) 0.36
Non-demented, n (%) 36 (6.3) 5 (0.8) <0.0001
“Normal cognition” cases, n (%) 15 (2.7) 2 (0.3) 0.0005
MCI cases, n (%) 18 (3.2) 3 (0.5) 0.0003
Months between final evaluation and death, Mean ± SEM 12.4 ± 0.4 14.8 ± 0.4 <0.0001
Nun Study cases, n 64 87
Adjusted* Final MMSE score, Mean ± SEM 14.9 ± 1.1 5.8 ± 1.0 <0.0001
Male gender, n (%) 0.0 0.0
Age at death, Mean ± SEM 91.4 ± 0.6 89.3 ± 0.5 0.0083
Maximum education level in years, Mean ± SEM 15.6 ± 0.4 15.0 ± 0.4 0.26
Neocortical Lewy bodies, n (%) 2 (3.1) 5 (5.7) 0.45
Hippocampal sclerosis, n (%) 8 (12.5) 15 (17.2) 0.42
Non-demented, n (%) 27 (42.2) 8 (9.2) <0.0001
“Normal cognition” cases not assessed
MCI cases not assessed
Months between final evaluation and death, Mean ± SEM 9.4 ± 0.8 9.8 ± 0.7 0.68
*

Adjusted for age at death and education.